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 !&!
Although rare, 3p microdeletion cases have been well described in the clinical 
literature. The clinical phenotype includes; intellectual disability (ID), growth 
retardation, facial dysmorphism and cardiac malformations. Advances in 
chromosome microarray (CMA) testing narrowed the 3p25 critical region to a 124kb 
region, and recent Whole Exome Sequencing (WES) studies have suggested that 
the  gene contributes significantly to the 3p25 phenotype. Loss6of6Function 
(LoF) variants in  are now considered a likely cause of ID. 
 We report here a patient with a frameshift LoF variant in exon 12 of . 
This patient has features overlapping with other patients described with LoF 
variants to include; similar facial morphology, feeding difficulties, intellectual 
disability, behavioural abnormalities and leg length discrepancy. In addition, he 
presents with an aberrant blind ending bronchus.  
 This report adds to publications describing intragenic mutations in  and 
supports the assertion that 	

 LoF mutations in  present with an 
overlapping but distinct phenotype in comparison with 3p25 microdeletion 
syndromes. 

'()*& 
3p microdeletion, 3p25, , aberrant blind ending bronchus, intellectual 
disability, loss of function. 




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,!&*-!*, 
 Intellectual Disability (ID) has a worldwide prevalence of approximately 1%6
3% and has become the most frequent reason for referral to paediatric genetic 
services [Maulik and Darmstadt 2007]. Due to its clinical and genetic heterogeneity, 
the underlying cause for ID remains unclear. However, advances in genetic testing 
have led to the elucidation of several novel genes linked to ID, some of the most 
successful studies have led to the identification of de novo LoF sequence variants in 
candidate genes [de Ligt and others 2012; Rauch and others; Vissers and others 
2010]. 
Distal deletions of the short arm of chromosome 3 were first characterised by 
cytogenetic and FISH analysis [Aqua and others 1995; Verjaal and De Nef 1978]. 
This condition results in a well6described syndrome associated with a clinical 
phenotype that includes; intellectual disability, growth retardation, facial 
dysmorphism and cardiac malformations.  The severity of the condition varies 
considerably, with the size of the deletion apparently correlating with the severity of 
the phenotype [Drumheller and others 1996].  
A report by Kellogg and others [2013] described 4 patients with 3p25.3 
deletions and ID, including 3 previously reported patients by Peltekova and others 
[2012], Riess and others [2012] and Gunnarsson and Foyn Bruun [2010]. These 
3p25.3 deletion carriers had a narrow range of overlap comprising of 3 genes 
including . In addition to ID, patients had a common phenotype of depressed 
nasal bridge (3/4), low set ears (3/4) and philtrum differences (3/4).  Other features 
were more variable including; cardiac malformations (2/4), ptosis (2/4), low birth 
weight/growth retardation (2/4), seizures (2/4) and microcephaly (2/4) [Kellogg and 
others 2013]. 
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Following this, 7 patients with independent LoF variants in from a 
cohort of 996 patients with moderate/severe ID (0.7% of cohort) were reported. 
Features included; speech delay, behavioural problems and autism. Similar 
dysmorphology i.e. brachycephaly, prominent forehead, abnormal eyebrows, similar 
nose morphology (long, thin, tubular), eye morphology (long, narrow, upslanting 
palpebral fissures, mild ptosis, unilateral amblyopia, nystagmus, strabismus) and 
large, fleshy, low set ears were reported. Again, more variable features included; 
cardiac malformations (2/7), skeletal abnormalities (leg length discrepancy, scoliosis, 
kyphosis, lordosis) and genitourinary abnormalities (4/7) [Grozeva and others 2014]. 
Kuechler and others [2015] went on to expand the phenotype further and 
described 4 unrelated patients with 4 different non6recurrent microdeletions on 
chromosome 3p25 narrowing down the smallest region of overlap to 94kb including 
only 2 coding genes, and parts of THUMPD3.  Included in the cohort were 2 
patients with intragenic  variants. Patients were compared with those from 
Kellogg and others [2013], Peltekova and others [2012], Riess and others [2012] and 
Gunnarsson and Foyn Bruun [2010]. Both microdeletion carriers and intragenic 
 variant carriers had a similar craniofacial phenotype of striking eyebrows 
(full, broad, straight, arched or with synophyrys), a tubular nose with broad nasal 
bridge, bulbous nasal tip, anteverted nares, a long philtrum and downturned corners 
of the mouth. Just like previous reports, features which showed incomplete 
penetrance were cardiac malformations and postaxial polydactyly.  
An emerging behavioural phenotype was supported with almost all the LoF 
mutation carriers and 3 microdeletion carriers showing some behavioural problems. 
Patients with larger deletions had additional facial differences (blepharophimosis, 
abnormal slanting of palpebral fissures and ptosis). Microdeletion carriers were more 
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likely to be of short stature, microcephalic and hypotonic and microdeletion carriers 
also showed more severe speech impairment. 
The only published cases of an inherited  variant suggested a more 
variable phenotype. Two siblings with developmental delay and features consistent 
with previously reported 	

 cases were compared to their father who 
had only mild intellectual impairment with some features of . These patients 
did not have ritualised behaviour or autism, abnormalities in eye structure, 
gastrointestinal and/or abdominal wall defects or scoliosis/kyphosis [Szczałuba and 
others 2016]. 
Frequency data for mutations is difficult to obtain. However, the 
genetic database Decipher includes 34 patients with  sequence variants 
(https://decipher.sanger.ac.uk/), the SFARI database of genes linked with autism has 
47  mutations reported in its human gene module (https://sfari.org/) and a 
recent large study of 4,293 patients recruited from the Deciphering Developmental 
Disorders (DDD) study identified 17patients with	

mutations 
[Deciphering Developmental Disorders 2017].   is, therefore, likely one of the 
most commonly mutated genes in developmental disorders [Deciphering 
Developmental Disorders 2017].  
 Adding to published reports, we present a patient with a 	

 
heterozygous c.1381_1388del, p.(Asn461fs) frameshift mutation in exon 12 of 
,who also has an aberrant blind ending bronchus, thus expanding the 
phenotype. 



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1!& ,1!2* 
  This patient was recruited to the Deciphering Developmental Disorders 
(DDD) study. Trio6based exome sequencing was performed on the affected 
individual and their parents, as previously described [Wright and others 2014].  Each 
affected individual also had a high6resolution analysis for copy number abnormalities 
using array6based comparative genomic hybridization (aCGH).  Putative 	


mutations were identified from exome data using DeNovoGear software [Ramu and 
others 2013] and were validated using targeted Sanger sequencing. Mutation 
nomenclature is according to HGVS guidelines with reference transcript 
NM_001080517.2. 
,&3*&!
This patient is the second child of healthy non6consanguineous, White 
European parents with unremarkable family history. He was born at term with a birth 
weight of 2.976kg, following an uneventful pregnancy. Raised alpha fetoprotein 
(AFP) levels were noted but antenatal scans were normal. There were no postnatal 
complications. Failure to thrive and difficulty gaining weight were noted and he later 
required fundoplication. He was born with postaxial polydactyly in all extremities 
requiring surgical removal at the age of 4 months and tongue tie. Persistent cough 
was noted at age 2 days and recurrent infections have continued to affect him, with a 
later diagnosis of asthma.  His chest infections were thought to be due to an aberrant 
blind ending bronchus identified on bronchoscopy. There were no concerns with his 
vision but conductive hearing loss was treated with grommet insertion. 
 Developmentally, at 10 months he could not sit unaided, he walked at 23 
months. Leg asymmetry was detected subsequently.  His first word was at 13 
months, with a vocabulary of single words at 2 years. At a clinical psychologist 
Page 6 of 19
John Wiley & Sons, Inc.
American Journal of Medical Genetics: Part A
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
For Peer Review
G r e e n  e t  a l .  P a g e  | 4
 
assessment at 5 ½ years old, a Verbal IQ of 83 (13th percentile) and Performance 
IQ of 98 (45th percentile) were recorded. Assessment also showed some weakness 
in social communication and a stutter with recurrent dribbling. However, he did not 
fulfil criteria for Autistic Spectrum Disorder.  At age 7, he was attending mainstream 
school with additional support. He was reported at school to have a dyslexic profile 
with ‘low average’ level.  In terms of behaviour, repetitive stereotyped behaviours 
were noted such as repeatedly touching his face. He was late to develop imaginary 
play and weakness in social interaction with peers was noted. Reassessment at age 
9 highlighted his complex communication needs and problems acquiring language 
skills.  
 On examination age 2 ½, he was noted to have brachycephaly with 
prominence in forehead, metopic ridge, hypertelorism, clinodactyly and prominent 
left ear (Figure 1 which shows evolving facial dysmorphism with age). Left leg was 2 
cms longer than right with a small café au lait mark (0.5cm) on left leg. Height was 
89cm (25th centile), weight was 13.11kg (25th centile), and head circumference was 
49cm (2nd69th centile).  
 Investigations included metabolic tests; urine organic acids and amino acids, 
creatine kinase, alpha feta protein, thyroid function, mucopolysaccharides were 
normal. Echocardiogram and renal ultrasound were also reported normal. 
Cytogenetics showed a normal male karyotype (46,XY) and FISH testing for deletion 
or duplication of the TBX1 locus at 22q11.2 was negative.  Testing for primary ciliary 
dyskinesia was also normal along with normal ophthalmology assessment which 
included electroretinogram. Panel genetic testing for Bardet Biedl Syndrome was 
normal. Patient was enrolled in the Deciphering Developmental Delay (DDD) 
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[DECIPHER ID: 259090] study which identified a de novo heterozygous 
c.1381_1388del, p.(Asn461fs) frameshift mutation in exon 12 of .   
 -  *,
The 3p critical region was initially thought to be a 365Mb region [Aqua and 
others 1995]. Subsequent patients were described with a narrow region of 
overlapping regions [Gunnarsson and Foyn Bruun 2010; Kellogg and others 2013; 
Peltekova and others 2012; Riess and others 2012] and was considered to 
be the strongest candidate gene [Peltekova and others 2012; Shuib and others 
2009]. Further evidence to support pathogenicity of, came from large cohorts 
of	

mutation carriers [Iossifov and others 2014; Pinto and others 2016; 
Rauch and others 2012; Deciphering Developmental Disorders 2017]. 
The coding sequence of  is 4329bp long and encodes 1442 amino 
acids. It is ubiquitously expressed and high levels have been seen in the cerebral 
cortex, the intestine and the eye [Kuechler and others 2015; Nagase and others 
1997]. The gene is highly evolutionarily conserved suggesting that it is functionally 
important and is considered a member of the ‘writers’ group of epigenetic genes 
[Kleefstra and others 2006].  
	
 domain analysis has showed that SETD5 is a multidomain protein 
containing a SET domain and a putative PHD domain [Kuechler and others 2015]. It 
thought have an important role in cell replication and gene expression through 
regulation of histone acetylation [Hu and others 2010; Jones and others 2008; 
Tanaka and others 2000; Yao and others 1998]. Genes encoding histone modifiers 
are increasingly recognised to have a contribution to ID [Berdasco and Esteller 
2013].  
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Animal models have demonstrated that is important in mammalian 
development with  deficient mouse embryos exhibiting severe developmental 
delay, vascular abnormalities, apoptosis, and reduced cellular proliferation; findings 
consistent with impairment of gene expression [Osipovich and others 2016].  
Histone modifier genes are all dosage sensitive and haploinsufficiency is 
believed to be the disease mechanism. 	
 analysis has shown that variants in 
 trigger nonsense mediated decay (NMD) pointing to LoF [Kuechler and 
others 2015]. Haploinsufficiency of a single gene has also proven to be casual for 
the specific phenotype in a number of microdeletion syndromes. There are several 
examples of this including;  in association with 9q34 deletion and  in 
association with 2q33.1 deletion.  
The phenotypic features of our patient with a 	

 variant fit with 
previously described patients to include; ID, language delay, ritualised behaviour, 
feeding difficulties, abnormal ears, eyebrows, shape of nose and polydactyly (see 
Table I). Common features described in the literature that our patient did not have 
include; micrognathia (8/13), thin upper lip (8/13), gastrointestinal defects (5/13) and 
genitourinary defects (6/13).  
The observation of brachycephaly was made only in our patient and 3 patients 
in the Grozeva and others [2014] cohort (3/7). Unsteady gait and hypertelorism are 
only described in our patient and 1 of the patients in the Szczałuba and others [2016] 
paper. 
Congenital heart defects appear to be more of a feature of the microdeletion 
syndrome [Gunnarsson and Foyn Bruun 2010; Peltekova and others 2012] with only 
4/13 patients in the  group affected. Knockout mice models have shown that 
 may be important for embryonic stem cells to differentiate into 
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cardiomyocytes [Osipovich and others 2016] and given the nature of cardiac 
anomalies reported in the literature, it is reasonable to consider a cardiac 
assessment at the time of initial diagnosis. 
Behavioural problems including obsessive compulsive disorder (OCD) and 
autism were common findings (6/13). Most of the patients with  pathogenic 
variants have truncating variants (frameshift or nonsense variants) and whilst some 
	

 missense variants have been reported in large cohorts of autism patients as 
being causative, extended phenotypic descriptions are not available to assign 
causality (Table I).  Based on data presented by [Li and others 2016; Neale and 
others 2012] there is insufficient evidence to link the reported  missense 
variants with autism or susceptibility to autism. Our patient had been assessed for 
autism but did not meet criteria for a diagnosis. He did show signs of ritualised 
behaviour with some areas of weakness in social communication. This is 
increasingly being observed in children with underlying genetic conditions 
contributing to their behaviour profile i.e. their behavioural problems are not typical 
and hence, will not fulfil the diagnostic criteria for autism spectrum disorder. 
However, it is well–recognised that their learning needs and behavioural traits can be 
challenging to manage and needs appropriate assessment to tailor resources to their 
needs. 
The notable difference in our patient is the presence of a blind6ending 
bronchus. Although recent studies have highlighted the integral role of in 
mammalian development, it remains unclear if the blind ending bronchus is related to 
the  mutation or whether it has an independent cause.  


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*,- *,
We report a 106year old boy with a 	

 LoF variant in  and provide 
a comprehensive review of published literature on this frequently reported ID gene. 
The emerging phenotype includes; ID, facial dysmorphology, skeletal anomalies, 
behavioural problems and speech and language difficulties. We report for the first 
time, aberrant blind ending bronchus as a possible association with this phenotype. 
Further case reports of this nature are required to expand the phenotype and 
understand variable expressivity of  especially as genomic sequencing 
studies identify variants of interest in this gene. 
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7-&,!7, 
	" Facial dysmorphism of this patient evolving with age demonstrating 
prominent forehead, upslanting palpebral fissures, bilateral low6set, posteriorly 
rotated ears, smooth philtrum. 
!"Clinical features of patients with 	

  variants in comparison to 
our patient. 
',*)71,! 
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